Hydofon

Hydromorphone, the active ingredient in Hydofon, is an opioid analgesic presented as an injection solution for intravenous and subcutaneous use. It is indicated for the management of severe acute pain, post‑operative pain, and cancer‑related pain in adult patients requiring rapid and potent analgesia. Administration is performed under strict medical supervision to monitor efficacy and safety.

GNH USA supplies Hydofon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, sourcing the product from EU‑regulated manufacturers to ensure compliance with stringent quality standards.

Hydromorphone is an opioid analgesic used to manage severe pain conditions.

Severe acute pain: provides rapid, potent analgesia for intense, short‑term pain episodes. Post‑operative pain: reduces pain following surgical procedures, facilitating recovery. Cancer‑related pain: controls persistent pain associated with malignant disease. Severe chronic pain: offers sustained analgesia for patients with ongoing severe pain unresponsive to other therapies.

Hydromorphone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: feeling of sickness often occurring shortly after administration. - Constipation: reduced bowel motility leading to hard stools. - Drowsiness: increased sleepiness or reduced alertness. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Respiratory depression: marked reduction in breathing rate that can be life‑threatening. - Severe hypotension: sudden drop in blood pressure causing faintness or shock. - Anaphylaxis: rare allergic reaction with rash, swelling, and airway compromise.

When using Hydofon, careful assessment and monitoring are essential to minimize risks.

Assess respiratory status: monitor breathing rate and oxygen saturation before and during therapy. Evaluate renal and hepatic function: adjust use in patients with impairment. Check for hypersensitivity: avoid in individuals with known allergy to hydromorphone or opioids. Use lowest effective dose in elderly: increased sensitivity to opioid effects. Avoid concurrent CNS depressants: heightened risk of sedation and respiratory depression. Store at controlled room temperature: keep in original container, protect from light and moisture.

Hydromorphone can interact with other medicines, altering its safety profile.

Major Interactions (Avoid): - Concomitant use with other opioids: additive respiratory depression. - Benzodiazepines or barbiturates: increased sedation and respiratory risk. - MAO inhibitors: risk of severe hypotension and serotonin syndrome.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of serotonin syndrome. - Anticholinergic agents: may worsen constipation. - Alcohol: enhances central nervous system depression.